The research you fund through LCRF is making meaningful progress in the fight against lung cancer. We are pleased to share our 2023 grantees’ one-year updates in this series.
Lloyd Bod, PhD
Massachusetts General Hospital
2023 LCRF Minority Career Development Award (CDA) in Lung Cancer
What he’s doing:
Dr. Bod is harnessing the power of immune cells to fight lung cancer, specifically by targeting B cells and a molecule called Tim-1.
How it’s going:
Tim-1 plays a critical role in suppressing immune responses, and by inhibiting this checkpoint, Dr. Bod is enhancing the body’s ability to fight cancer. In animal models, combining Tim-1 inhibitors with PD-L1 inhibitors—a key component of current immunotherapies—has shown promising results in improving anti-cancer effects.
What it could mean for patients:
This research is still in its early stages, but the potential for this combination therapy to boost immunotherapy effectiveness could offer new hope for lung cancer patients, especially those whose cancers are resistant to current treatments.